How to Help Your Patients Save Money on Mirabegron XR: A Provider's Guide to Savings Programs

Cost is one of the most significant barriers to adherence for overactive bladder patients taking Mirabegron XR (Myrbetriq). At $450 to $625 per month for brand Myrbetriq without insurance assistance, patients who encounter formulary changes, step therapy barriers, or supply issues may simply stop taking their medication. In 2026, with additional insurance access challenges layered on top of generic supply disruptions, proactive cost support has become an essential part of prescribing Mirabegron XR. This guide gives providers a practical framework for identifying the right cost-reduction strategy for each patient.

Understanding the Cost Landscape for Mirabegron XR in 2026

Two cost challenges are prominent in 2026:

Generic supply disruption: A federal court injunction in April 2025 blocked two major generic mirabegron manufacturers (Lupin and Zydus) from selling their products. This means patients who had been successfully using lower-cost generic mirabegron may now face supply gaps, forcing them to pay brand prices or go without.

Insurance step therapy barriers: UnitedHealthcare and affiliated plans implemented step therapy requirements for mirabegron effective November 2025, requiring patients to fail two alternative OAB drugs before coverage begins. Patients in the step therapy process may be paying out of pocket while waiting for PA approvals.

Program 1: Astellas Momentum Savings Card — For Commercially Insured Patients

The Astellas Momentum Savings Card (also called the Myrbetriq Savings Card) is a manufacturer-sponsored copay assistance program for patients with commercial health insurance. This card reduces the out-of-pocket cost at the pharmacy when brand-name Myrbetriq is prescribed.

Eligible patients: Commercially insured patients (employer plans, individual market ACA plans). NOT for Medicare, Medicaid, TRICARE, or other federal program beneficiaries.

How to access: Patients can enroll at myrbetriq.com or through Astellas patient support. Some practices keep enrollment cards in the office to give directly to patients.

Provider tip: When prescribing Myrbetriq to commercially insured patients, hand out or verbally recommend the savings card at the point of prescription. This single step can dramatically improve adherence by preventing the initial sticker shock at the pharmacy.

Program 2: Astellas Patient Assistance Program (PAP) — For Uninsured/Underinsured Patients

The Astellas Patient Assistance Program provides Myrbetriq at reduced or no cost for patients who are uninsured or underinsured and meet income eligibility criteria. Eligibility is typically based on household income relative to the federal poverty level.

Who qualifies: Uninsured or underinsured patients meeting income limits. Eligibility is determined on a case-by-case basis.

How to apply: Your office staff or a social worker can help complete the application. Contact Astellas patient support or visit the manufacturer website for current application requirements.

Practice tip: Identify uninsured or underinsured patients at the time of prescription using intake forms or insurance verification. Connect them with your medical assistant or social worker to initiate PAP enrollment before they leave the office.

Program 3: GoodRx and SingleCare — For Generic Mirabegron When Available

When generic mirabegron extended-release is available at a local pharmacy, GoodRx and SingleCare coupons can bring the cost to approximately $121-$189 per month — well below the retail price of $450-$663. These discount programs work for any patient paying cash, regardless of insurance status.

However, due to the patent litigation supply disruption affecting Lupin and Zydus, generic mirabegron may not be available at every pharmacy. Patients may need to call around to find a pharmacy with stock before the coupon is useful. Recommending medfinder alongside GoodRx can help patients find both the stock and the savings at the same time.

38,912+ patients found their medications in stock

38K+

Find Mirabegron XR In Stock Today →

Program 4: Medicare Extra Help (Low-Income Subsidy) — For Medicare Patients with Low Income

For Medicare Part D beneficiaries with limited income and resources, the federal Extra Help program (also called Low-Income Subsidy or LIS) can significantly reduce prescription out-of-pocket costs. As of 2026, Medicare Part D has an annual $2,100 out-of-pocket cap for covered medications. Extra Help lowers premiums, deductibles, and copays further for eligible patients.

Eligible patients can apply through the Social Security Administration. Your practice's social worker or care coordinator can help identify Medicare patients who may not be enrolled in Extra Help despite qualifying.

Prior Authorization Strategy: Reducing the Step Therapy Burden

For patients whose insurance requires step therapy, a successful PA exception is the most direct path to covered Mirabegron XR. When building the PA, cost data supports the clinical argument: patients who don't adhere to OAB medication often have complications (falls from urgency, worsening quality of life, recurrent UTIs) that cost the payer far more than the medication itself.

Strong PA documentation points for mirabegron include:

Documented history of anticholinergic intolerance (any OAB drug)

Age ≥65 with cognitive risk or dementia — Beers Criteria contraindication to antimuscarinics

Comorbid constipation requiring treatment — antimuscarinics will worsen this

Clinical stability on existing mirabegron therapy — disrupting a working treatment is medically inappropriate

Documented OAB quality-of-life scores showing improvement on mirabegron

Skip the calls, skip the stress.

Find Mirabegron XR In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Practice Workflow: A Proactive Cost Support Model

Consider implementing this workflow in your practice for every new Mirabegron XR prescription:

At time of prescription: Check patient insurance type. Commercial → offer savings card. Uninsured/underinsured → initiate PAP enrollment. Medicare with low income → refer for Extra Help screening.

At prescription transmission: Specify DAW (Dispense as Written) only if brand is clinically preferred; otherwise allow generic substitution to enable GoodRx pricing.

If patient calls with fill difficulty: Triage immediately — supply problem or insurance problem? Direct to medfinder for supply, initiate PA for coverage.

At follow-up: Ask directly "Were you able to fill your Mirabegron XR? Was the cost manageable?" Adherence questions caught early prevent treatment failures.

When Savings Programs Cannot Solve the Problem: Consider Vibegron

For patients who cannot access mirabegron through any savings pathway, vibegron (Gemtesa 75 mg daily) is the pharmacologically closest alternative. It works through the same beta-3 mechanism and avoids the CYP2D6 interaction risk. Urovant Sciences offers its own savings programs for Gemtesa — check its website for current copay assistance for commercially insured patients.

For resources to share with your patients on finding Mirabegron XR in stock near them, visit medfinder for providers. medfinder is a paid service that calls pharmacies on behalf of patients to find which ones have their specific medication in stock, then texts results directly to the patient.